In its 17th annual report, the Resource Tracking for HIV Prevention Research & Development Working Group documents research and development spending for the calendar year 2021. This report also analyzes funding trends spanning 22 years for the following biomedical HIV prevention options: preventive HIV vaccines, microbicides, pre-exposure prophylaxis (PrEP), treatment as prevention (TasP), voluntary medical male circumcision (VMMC), female condoms and prevention of vertical transmission (PVT). More information at hivresourcetracking.org.
HIV Prevention Research & Development Investments 2021
Evolving Strategies for an HIV Vaccine: One researcher explains where the field is going and why?
May 17, 2023
With several large HIV vaccine trials in the last few years finding no efficacy, the field is in transition. There are diverse ideas in vaccine research, but there’s no clear concept that’s ready to test in a late-phase trial or move towards product development currently. Researchers are back to testing new ideas in early phase research.
In this episode of our Px Pulse podcast, Evolving Strategies for an HIV Vaccine: One researcher explains where the field is going and why?, Dr. Katy Stephenson explores the implications of recent trial results, the big questions driving next generation vaccine development, and new strategies underway in early phase research. Katy is a doctor, a researcher, a professor of medicine at Harvard Medical School, affiliated with Beth Israel Deaconess Medical Center, and part of the Center for Virology and Vaccine Research.
Listen
Resources
HIV Vaccine Awareness Day (HVAD) 2023
In 2023, AVAC and CASPR partners cast a spotlight on many issues and opportunities for HIV vaccine science. This one-pager highlights key conversations.
Global Investment in HIV Cure Research & Development in 2021
A decade of progress
Language for HIV Cure
This document shares up-to-date, community-preferred terminology within cure research.
A Comprehensive Approach for Progress
Ending the Epidemic
HIV-Specific Neutralizing Antibodies by Target
A number of broadly neutralizing antibodies that target various regions of HIV’s Env protein are being developed for HIV prevention.
The Case For an HIV Cure and How to Get There
Viewpoint appearing in The Lancet HIV
Appearing in The Lancet HIV: We propose steps to plan for an HIV cure now, including defining a target product profile and establishing the HIV Cure Africa Acceleration Partnership (HCAAP), a multidisciplinary public-private partnership that will catalyse and promote HIV cure research through diverse stakeholder engagement. HCAAP will convene stakeholders, including people living with HIV, at an early stage to accelerate the design, social acceptability, and rapid adoption of HIV-cure products.
What’s All the Buzz About: mRNA, manufacturing, vaccine access
Exploring the potential role of bNAbs in prevention
AVAC and partners hosted a conversation to explore the potential role of bNAbs in prevention, current status in the field, and key issues to consider in HIV vaccine research.
Panelists included: Slim Karim, CAPRISA, Pervin Anklesaria, Bill & Melinda Gates Foundation, Khadija Richards, Wits RHI, Huub Gelderblom, HIV Vaccine Trials Network (HVTN)
Hosted By: Mitchell Warren, AVAC and Stacey Hannah, AVAC
Recording / Slim Karim Slides / Pervin Anklesaria Slides / Khadija Richards Slides / Huub Gelderblom Slides
AVAC Partnership Strategy 2023-2026
This document lays out AVAC’s plan to transition away from traditional power structures when working with partners — from civil society advocates to scientists, policy makers, program implementers, and more. AVAC strives towards a model in which those with lived experience and field expertise have influence and equal voice in the design and delivery of plans and priorities.